Sen. John Boozman Sells Off Shares of AbbVie Inc. (NYSE:ABBV)

Key Points

• Senator John Boozman disclosed the sale of shares in AbbVie Inc. (NYSE:ABBV) between $1,001 and $15,000 on August 22nd, as part of various trades that also included purchases of NVIDIA and Eli Lilly shares.
• AbbVie reported a net margin of 6.45% and a revenue of $15.42 billion for the last quarter, exceeding analysts' estimates.
• The company announced a quarterly dividend of $1.64 per share, scheduled to be paid on November 14th, representing a dividend yield of 3.0%.

Senator John Boozman (R-Arkansas) recently sold shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on September 12th, the Senator disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on August 22nd.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 8/22/2025.
• Sold $1,001 - $15,000 in shares of Micron Technology NASDAQ: MU on 8/22/2025.
• Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/22/2025.
• Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/11/2025.
• Sold $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 8/11/2025.
• Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of iShares MBS ETF NASDAQ: MBB on 8/1/2025.
• Sold $1,001 - $15,000 in shares of iShares MSCI EAFE ETF NYSEARCA: EFA on 8/1/2025.
• Purchased $1,001 - $15,000 in shares of Goldman Sachs ActiveBeta Emerging Markets Equity ETF NYSEARCA: GEM on 8/1/2025.
• Purchased $1,001 - $15,000 in shares of iShares 7-10 Year Treasury Bond ETF NASDAQ: IEF on 8/1/2025.

AbbVie Stock Down 0.8%

Shares of NYSE ABBV traded down $1.82 during trading on Friday, reaching $218.40. 4,418,717 shares of the stock were exchanged, compared to its average volume of 4,347,903. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The business's 50-day moving average price is $200.25 and its 200 day moving average price is $194.52. The company has a market capitalization of $385.82 billion, a price-to-earnings ratio of 104.00, a price-to-earnings-growth ratio of 1.42 and a beta of 0.53. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $221.76.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. During the same quarter in the prior year, the company earned $2.65 EPS. The business's quarterly revenue was up 6.6% on a year-over-year basis. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be given a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, October 15th. AbbVie's payout ratio is presently 312.38%.

Institutional Trading of AbbVie

Several large investors have recently modified their holdings of the stock. Marshall & Sullivan Inc. WA bought a new position in AbbVie in the second quarter valued at about $25,000. Evolution Wealth Management Inc. acquired a new stake in AbbVie in the second quarter valued at approximately $26,000. TD Capital Management LLC grew its stake in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after acquiring an additional 58 shares during the period. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the second quarter valued at approximately $28,000. Finally, Abound Financial LLC purchased a new position in AbbVie in the first quarter worth $30,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president owned 177,292 shares of the company's stock, valued at $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the sale, the executive vice president owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.25% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ABBV. BMO Capital Markets increased their price objective on AbbVie from $215.00 to $240.00 and gave the company an "outperform" rating in a research report on Friday. Guggenheim raised their target price on AbbVie from $216.00 to $227.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Citigroup lifted their price objective on AbbVie to $205.00 and gave the stock a "hold" rating in a research report on Wednesday, June 11th. Daiwa America upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 7th. Finally, Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Four analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of "Moderate Buy" and a consensus price target of $217.10.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas' U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman's academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.